You might also like
LivaNova PLC (LIVN) is a global medical technology company headquartered in London, England. The company specializes in designing, developing, manufacturing, and selling innovative medical products and therapies aimed at improving patient outcomes. Its offerings focus on cardiopulmonary bypass procedures and neuromodulation therapies for neurological and sleep-related conditions.
-
Cardiopulmonary - Develops and markets products for cardiopulmonary bypass procedures, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, and related accessories. Features the Essenz Perfusion System, a next-generation heart-lung machine with advanced monitoring and sensing technology.
-
Neuromodulation - Provides devices for neuromodulation therapy, including the VNS Therapy System for treating drug-resistant epilepsy and depression, and the aura6000 System for obstructive sleep apnea, which is under clinical testing.
-
Other/Advanced Circulatory Support (ACS) - Previously included temporary life support products like LifeSPARC and Hemolung systems, with some products integrated into Cardiopulmonary and others discontinued as part of a restructuring plan.
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Vladimir Makatsaria ExecutiveBoard | Chief Executive Officer | Chairman of APACMed; Advisory Board Member at Singapore Management University | Former Johnson & Johnson executive with nearly 30 years in healthcare. Appointed CEO of LivaNova in March 2024. | View Report → |
Alex Shvartsburg Executive | Chief Financial Officer | None | Joined LivaNova in 2017; became permanent CFO in July 2021. Previously held leadership roles at Thermo Fisher Scientific and Johnson & Johnson. | |
Michael Hutchinson Executive | Chief Legal Officer | None | Joined LivaNova in November 2022. Formerly held senior legal roles at Stryker and Varian Medical Systems. | |
Stephanie Bolton Executive | President, Global Epilepsy | Vice Chair of the Association of British HealthTech Industries | Joined LivaNova in 2011. Held various leadership roles in epilepsy and cardiopulmonary businesses. Appointed President of Global Epilepsy in May 2023. | |
Brooke Story Board | Director | None | Director at LivaNova since 2022. Former executive at BD and Medtronic. | |
Dr. Sharon O’Kane Board | Director | Non-executive director at Health Products Regulatory Authority (Ireland); Entrepreneur in Residence at University College Dublin; Visiting Professor at Ulster University | Co-founder of Renovo Group Plc. Director at LivaNova since 2015. Extensive experience in biotech and healthcare. | |
Francesco Bianchi Board | Director | Chair of Seven Capital Partners S.r.l. | Director at LivaNova since 2015. Extensive experience in mergers and acquisitions and strategic advisory roles. | |
J. Christopher Barry Board | Director | EVP and Group President, Medical Solutions Division at 3M Company | Former CEO of NuVasive, Inc. and senior executive at Medtronic. Appointed to LivaNova's Board in October 2023. | |
Peter Wilver Board | Director | Director at Baxter International Inc. and Shoals Technologies Group, Inc. | Director at LivaNova since 2022. Former CFO of Thermo Fisher Scientific. | |
Stacy Enxing Seng Board | Director | Operating Partner at Lightstone Ventures; Director at Sonova Holding AG | Director at LivaNova since 2019. Extensive experience in medical technology and venture capital. | |
Susan Podlogar Board | Director | None | Director at LivaNova since October 2024. Former CHRO at MetLife and Johnson & Johnson. | |
Todd Schermerhorn Board | Director | Director at The Travelers Companies, Inc. | Director at LivaNova since 2020. Former CFO of C.R. Bard, Inc. | |
William Kozy Board | Chair of the Board of Directors | Vice Chair and Lead Director at Cooper Companies, Inc. | Chair of LivaNova's Board since 2018. Former COO of Becton Dickinson. Served as interim CEO from April 2023 to February 2024. |
- Can you provide more details on your capacity expansion plans for oxygenators and how you intend to sustain the strong performance in this segment, particularly in light of competitor dynamics?
- With the anticipated increase in the effective tax rate to 24%-25% in 2025, how do you plan to achieve margin expansion and grow EPS faster than revenue, especially considering potential investments in DTD and OSA programs?
- Regarding your DTD program, can you elaborate on the timing of the CMS coverage decision and how potential delays might impact your investment plans and projected cost savings for 2025?
- In the epilepsy segment, given that approximately 40% of patients are on Medicare, how might potential changes in Medicare reimbursement affect your business, and could there be spillover effects on private insurers?
- As you approach 2025, how are you balancing R&D investments between high-risk programs like DTD and OSA and incremental innovations in your core businesses to support sustained growth and market share gains?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
Terumo Medical Corporation | A primary competitor in the Cardiopulmonary, Neuromodulation, and ACS product groups. The company operates in the global medical device market, which is characterized by rapid technological advances and scientific discoveries. |
Maquet Medical Systems | Competes with the company in the Cardiopulmonary, Neuromodulation, and ACS product groups, offering specialized medical devices in a highly competitive market. |
A significant competitor in the Cardiopulmonary, Neuromodulation, and ACS product groups, known for its broad range of medical devices and technologies. | |
Competes in the Cardiopulmonary, Neuromodulation, and ACS product groups, focusing on specialized medical devices and solutions. | |
NeuroPace, Inc. | A competitor in the Neuromodulation product group, providing alternative neuromodulation therapies. |
Competes in the Cardiopulmonary, Neuromodulation, and ACS product groups, offering a wide range of medical devices and technologies. |
Recent developments and announcements about LIVN.
Earnings
New Earnings (Q4 2024)
·Mar 7, 2025, 1:03 AMView full earnings summary →Despite capacity constraints, LIVN projects high single-digit cardiopulmonary growth, fueled by Essenz adoption climbing from 40% in 2024 to 60% in 2025. Q4 adjusted EPS dipped from $0.87 to $0.81, hit by a 300bp tax rate uptick. Capacity expansion remains key.
8-K Filings
8-K Filing
·3 days agoRegulation FD DisclosureView full 8-K filing →LivaNova reports a ruling from Italy’s Supreme Court on SNIA litigation. The company will record a liability of €333M ($363M) for Q1 2025. With $429M in cash and $295M in restricted cash, it remains well-capitalized to address these costs.